The methods of thrombolytic therapy for cerebral infarction include intravenous thrombolytic therapy and arterial thrombolytic therapy. Clinically, intravenous thrombolytic therapy is generally preferred, mainly applying alteplase and urokinase, which is applicable to patients in the hyperacute stage, meaning that the time of onset of the patient is within 6 hours. If the patient’s onset time is within 4.5 hours, intravenous thrombolysis with alteplase is clinically indicated. If the onset time is more than 4.5 hours and within 6 hours, clinical application of urokinase for intravenous thrombolysis is indicated. The main indications for intravenous thrombolysis include the patient’s age below 80 years old and the presence of severe somatic neurological signs and symptoms. The main indications include that the patient is under 80 years of age, has severe neurological symptoms and signs, and can be treated within 6 hours of the onset of the disease, and cranial CT excludes hemorrhage, and there is no change in the imaging of large cerebral infarction, and contraindications are excluded. Intravenous thrombolytic therapy can rapidly restore cerebral blood flow, improve brain tissue metabolism, protect the ischemic semidark zone tissue around the infarct with functional changes only, avoid the formation of necrosis, improve the symptoms and signs of neurological deficits to the maximum extent, and reduce the mortality and disability rate of patients.